Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.35 USD
Change Today +0.0115 / 3.40%
Volume 368.9K
ONCS On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

oncosec medical inc (ONCS) Snapshot

Open
$0.34
Previous Close
$0.34
Day High
$0.35
Day Low
$0.33
52 Week High
06/2/14 - $0.90
52 Week Low
03/13/15 - $0.31
Market Cap
86.5M
Average Volume 10 Days
1.3M
EPS TTM
$-0.08
Shares Outstanding
247.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOSEC MEDICAL INC (ONCS)

Related News

No related news articles were found.

oncosec medical inc (ONCS) Related Businessweek News

No Related Businessweek News Found

oncosec medical inc (ONCS) Details

OncoSec Medical Incorporated, a hybrid device and gene therapy biotechnology company, designs, develops, and commercializes medical approaches principally immunotherapy for the treatment of solid tumors in the United States. Its clinical programs include three Phase II clinical trials to assess the ImmunoPulse technology in patients with melanoma, Merkel cell carcinoma, and cutaneous T-cell lymphoma. It has a collaboration agreement with Heat Biologics, Inc. to evaluate the combination of immunotherapy platforms. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated is headquartered in San Diego, California.

42 Employees
Last Reported Date: 10/10/14

oncosec medical inc (ONCS) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $467.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $310.0K
Chief Scientific Officer and Global Head of R...
Total Annual Compensation: $172.8K
Compensation as of Fiscal Year 2014.

oncosec medical inc (ONCS) Key Developments

OncoSec Medical Incorporated Announces Earnings Results for the Six Months Ended January 31, 2015

OncoSec Medical Incorporated announced earnings results for the six months ended January 31, 2015. For the period, the company reported net loss of $8.7 million, or $0.04 per share, compared to a net loss of $4.7 million, or $0.03 per share, for the same period last year. There were no revenues for the six months ended January 31, 2015 or January 31, 2014.

OncoSec Medical Incorporated and Merlin CSI, LLC Enter into Research and Development Services Agreement

On March 6, 2015, OncoSec Medical Incorporated and Merlin CSI, LLC (Merlin) entered into a research and development services agreement. Pursuant to the Merlin R&D agreement, the Company has engaged Merlin to perform research, development, testing, and regulatory filing services for the Company related to two engineering projects pertaining to the next-generation of electroporation delivery devices. The company will own the rights to any intellectual property that developed in performing the services under the Merlin R&D agreement. The term of the Merlin R&D agreement began on March 6, 2015 and is expected to continue until the completion of the engineering projects, subject to either party's right to terminate the Merlin R&D agreement upon 30 days' written notice to the other party. The company expects to pay Merlin approximately $1,525,000 for its performance of services under the Merlin R&D agreement, plus potential additional costs, including preapproved expenses that may be incurred by Merlin.

OncoSec Medical Incorporated and Rev.1 Engineering Inc. Enter into Research and Development Services Agreement

OncoSec Medical Incorporated and Rev.1 Engineering Inc. entered into a Research and Development Services Agreement (the Rev.1 R&D Agreement). Pursuant to the Rev.1 R&D Agreement, the company has engaged Rev.1 to perform research, development, testing, and regulatory filing services for the Company related to two engineering projects pertaining to the next-generation of electroporation delivery devices. The Company will own the rights to any intellectual property that is developed in performing the services under the Rev.1 R&D Agreement. The term of the Rev.1 R&D Agreement began on March 6, 2015 and is expected to continue until the completion of the engineering projects, subject to either party's right to terminate the Rev.1 R&D Agreement upon 30 days' written notice to the other party. The Company expects to pay Rev.1 approximately $3,383,000 for its performance of services under the Rev.1 R&D Agreement, plus potential additional costs, including preapproved expenses that may be incurred by Rev.1. The Company paid an initial deposit to Rev.1 of $350,000, and Rev.1 will use this deposit to offset 10% of each monthly invoice under the Rev.1 R&D Agreement, reducing the outstanding deposit accordingly until the deposit has been fully applied.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONCS:US $0.35 USD +0.0115

ONCS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONCS.
View Industry Companies
 

Industry Analysis

ONCS

Industry Average

Valuation ONCS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOSEC MEDICAL INC, please visit www.oncosec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.